Press Releases

Our latest news and press releases

Cellectis to Participate in Two Upcoming Investor Conferences in March

Read more

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Read more

Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST

Read more

Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

Read more

Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer

Read more

Cellectis’ Licensed Partner, Allogene Therapeutics,  Announces Removal of FDA Clinical Hold on their Clinical Trials

Read more

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

Read more

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Read more

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Read more

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

Read more